282 related articles for article (PubMed ID: 37389304)
1. Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy.
Sembill JA; Lusse C; Linnerbauer M; Sprügel MI; Mrochen A; Knott M; Engelhorn T; Schmidt MA; Doerfler A; Oberstein TJ; Maler JM; Kornhuber J; Lewczuk P; Rothhammer V; Schwab S; Kuramatsu JB
Brain Commun; 2023; 5(3):fcad159. PubMed ID: 37389304
[TBL] [Abstract][Full Text] [Related]
2. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
[TBL] [Abstract][Full Text] [Related]
3. Characterizing mixed location hemorrhages/microbleeds with CSF markers.
Jensen-Kondering U; Margraf NG; Weiler C; Maetzler W; Dargvainiene J; Falk K; Philippen S; Bartsch T; Flüh C; Röcken C; Möller B; Royl G; Neumann A; Brüggemann N; Roeben B; Schulte C; Bender B; Berg D; Kuhlenbäumer G
Int J Stroke; 2023 Jul; 18(6):728-735. PubMed ID: 36622021
[TBL] [Abstract][Full Text] [Related]
4. Cerebral microbleeds topography and cerebrospinal fluid biomarkers in cognitive impairment.
Shams S; Granberg T; Martola J; Charidimou A; Li X; Shams M; Fereshtehnejad SM; Cavallin L; Aspelin P; Wiberg-Kristoffersen M; Wahlund LO
J Cereb Blood Flow Metab; 2017 Mar; 37(3):1006-1013. PubMed ID: 27178426
[TBL] [Abstract][Full Text] [Related]
5. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.
Renard D; Wacongne A; Ayrignac X; Charif M; Fourcade G; Azakri S; Le Floch A; Bouly S; Marelli C; Arquizan C; Hirtz C; Gabelle A; Thouvenot E; Lehmann S
J Alzheimers Dis; 2016; 50(3):759-764. PubMed ID: 26757185
[TBL] [Abstract][Full Text] [Related]
7. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
8. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A
J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis.
Margraf NG; Jensen-Kondering U; Weiler C; Leypoldt F; Maetzler W; Philippen S; Bartsch T; Flüh C; Röcken C; Möller B; Royl G; Neumann A; Brüggemann N; Roeben B; Schulte C; Bender B; Berg D; Kuhlenbäumer G
Front Aging Neurosci; 2022; 14():783996. PubMed ID: 35237145
[TBL] [Abstract][Full Text] [Related]
10. MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
Banerjee G; Kim HJ; Fox Z; Jäger HR; Wilson D; Charidimou A; Na HK; Na DL; Seo SW; Werring DJ
Brain; 2017 Apr; 140(4):1107-1116. PubMed ID: 28335021
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ42, and Aβ40 in Probable Cerebral Amyloid Angiopathy.
Grangeon L; Paquet C; Guey S; Zarea A; Martinaud O; Rotharmel M; Maltête D; Quillard-Muraine M; Nicolas G; Charbonnier C; Chabriat H; Wallon D
J Alzheimers Dis; 2022; 87(2):791-802. PubMed ID: 35367960
[TBL] [Abstract][Full Text] [Related]
13. Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration.
Ortner M; Goldhardt O; Diehl-Schmid J; Yakushev I; Lanz K; Hedderich DM; Manuilova E; Simon M; Weinberger JP; Grimmer T
J Prev Alzheimers Dis; 2022; 9(3):491-498. PubMed ID: 35841250
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid Biomarkers and Amyloid-β Elimination from the Brain in Cerebral Amyloid Angiopathy-Related Inflammation.
Sakai K; Noguchi-Shinohara M; Tanaka H; Ikeda T; Hamaguchi T; Kakita A; Yamada M; Ono K
J Alzheimers Dis; 2023; 91(3):1173-1183. PubMed ID: 36565118
[TBL] [Abstract][Full Text] [Related]
15. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients.
Gerards M; Schild AK; Meiberth D; Rostamzadeh A; Vehreschild JJ; Wingen-Heimann S; Johannis W; Martino Adami P; Onur OA; Ramirez A; Karikari TK; Ashton NJ; Zetterberg H; Blennow K; Maier F; Jessen F
Dement Geriatr Cogn Disord; 2022; 51(2):182-192. PubMed ID: 35504263
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid Biomarkers in Dementia Patients with Cerebral Amyloid Angiopathy.
Li YF; Ge FF; Zhang Y; You H; Zhang ZX
Chin Med Sci J; 2015 Sep; 30(3):170-3. PubMed ID: 26564416
[TBL] [Abstract][Full Text] [Related]
19. Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease.
Hajjar I; Okafor M; Wan L; Yang Z; Nye JA; Bohsali A; Shaw LM; Levey AI; Lah JJ; Calhoun VD; Moore RH; Goldstein FC
Brain Commun; 2022; 4(6):fcac270. PubMed ID: 36440097
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.
Almdahl IS; Lauridsen C; Selnes P; Kalheim LF; Coello C; Gajdzik B; Møller I; Wettergreen M; Grambaite R; Bjørnerud A; Bråthen G; Sando SB; White LR; Fladby T
Front Aging Neurosci; 2017; 9():9. PubMed ID: 28223932
[No Abstract] [Full Text] [Related]
[Next] [New Search]
